Dr. Lal PathLabs Ltd

Stage 2 · Advancing · week 18Setup 6.1 ★ FairStrong +7.2

As of 9 Oct 2026, Dr. Lal PathLabs is in Stage 2 — advancing, the uptrend phase, in week 18 (since 10 Jun 2026). It closed at ₹1,934, 3.6% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. More about the company

₹1,933.6
+1.83% today
₹32,287 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dHospitals & Diagnostic Centres 32.3%-6.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

6.1 ★ Fair

Momentum

Steady

Edge

Strong +7.2

Setup-score rank among Stage 2 peers: #2 of 10 in Hospitals & Diagnostic Centres · #24 of 78 in Health Care

Is LALPATHLAB early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-3.6%
₹1,307.6 lo₹2,005.1 hi
3.6% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 18
1w13w26w
Week 18 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
20.4%
200 DMA: ₹1,605.8 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.53x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +1.0% vs MA50 +4.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+1.1%
3M
+14.2%
6M
+40.3%
YTD
+37.4%
1Y
+22.6%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #38 of 74 Stage 2 stocks in Health Care by RS.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
32.3%
20d Δ
-6.5pp
1M return
-8.1%
3M return
-10.8%
Industry Stage-2 % · last 20 days
Ranks #4 of 9 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 27w
S2 22w
S4 14w
S2 14w
S4 16w
S2 17w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 27w → S3 7w → S4 9w → S1 2w → S2 22w → S3 12w → S4 14w → S1 10w → S2 14w → S3 11w → S4 16w → S1 5w → S2 17w current
Total tracked: 169 weeks across 14 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-06-10
3 appearances in last 60 days. First seen: 2024-06-10.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 18 · Vol 0.53x
2026-10-08S2
Wk 17 · Vol 0.85x
2026-10-07S2
Wk 17 · Vol 0.71x
2026-10-06S2
Wk 17 · Vol 0.64x
2026-10-05S2
Wk 17 · Vol 0.92x
2026-10-01S2
Wk 17 · Vol 1.46x
2026-09-30S2
Wk 16 · Vol 1.45x
2026-09-29S2
Wk 16 · Vol 1.12x
2026-09-28S2
Wk 16 · Vol 0.38x
2026-09-25S2
Wk 16 · Vol 1.27x
2026-09-24S2
Wk 16 · Vol 1.21x
2026-09-23S2
Wk 15 · Vol 0.65x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,922.5
200 DMA
₹1,605.8
52W High
₹2,005.1
52W Low
₹1,307.6
5D Low
₹1,898.9
Resistance levels (recent highs)
20d High
₹2,005.1
60d High
₹2,005.1
120d High
₹2,005.1
250d High
₹2,005.1
Next resistance
+3.7%
to 20d High
Ask the Market AI about LALPATHLABAsk →
P/E (TTM)
51.2
Forward 39.3
Earnings Growth (YoY)
-15.4%
Revenue +16.6%
ROE
+21.5%
Profit margin +18.3%
Dividend Yield
0.87%
P/B 11.3
About this companyHealth Care· Hospitals & Diagnostic Centres

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.